{"paper_id":"c32e2e4e-b069-49b7-9157-34ab338a0f35","body_text":"Abstract\nEndometriosis is a common gynecological disorder that can cause chronic pain and infertility. To better understand mechanisms of disease etiology and progression, researchers are increasingly turning to model systems. In vivo approaches have notable limitations, including limited ability to model human anatomy-related pathologies and poor translation of therapeutics developed in animal models. This chapter describes the current body of work surrounding the recent emergence of in vitro models of endometriosis. This work aims to describe methods by which researchers can consider specifying their work to stages of disease, lesion location, and interactions that could drive disease progression. This chapter defines a roadmap for the development of more robust and specific models of endometriosis with the goal of realizing translatable therapeutic strategies and noninvasive metrics of disease presence and progression.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nInternational Working Group of AAGL, ESGE, ESHRE and WES, et al. An international terminology for endometriosis, 2021†,‡. Hum Reprod Open. 2021;2021(4):hoab029.\nShigesi N, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):486–503.\nBougie O, Nwosu I, Warshafsky C. Revisiting the impact of race/ethnicity in endometriosis. Reprod Fertil. 2022;3(2):R34–41.\nFarland L, Horne A. Disparity in endometriosis diagnoses between racial/ethnic groups. BJOG: Int J Obstet Gynaecol. 2019;126(9):1115–6.\nKaton JG, Plowden TC, Marsh EE. Racial disparities in uterine fibroids and endometriosis: a systematic review and application of social, structural, and political context. Fertil Steril. 2023;119(3):355–63.\nKoninckx PR, et al. The epidemiology of endometriosis is poorly known as the pathophysiology and diagnosis are unclear. Best Pract Res Clin Obstet Gynaecol. 2021;71:14–26.\nBougie O, et al. Influence of race/ethnicity on prevalence and presentation of endometriosis: a systematic review and meta-analysis. BJOG: Int J Obstet Gynaecol. 2019;126(9):1104–15.\nMissmer SA, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol. 2004;160(8):784–96.\nParazzini F, Vercellini P, Pelucchi C. Endometriosis: epidemiology, and etiological factors. In: Giudice LC, Evers JLH, Healy DL, editors. Endometriosis: Science and practice, Blackwell Publishing Ltd; 2011:19–26. https://doi.org/10.1002/9781444398519\nParazzini F, et al. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017;209:3–7.\nMoen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand. 1993;72(7):560–4.\nLamb K, Hoffmann RG, Nichols TR. Family trait analysis: a case-control study of 43 women with endometriosis and their best friends. Am J Obstet Gynecol. 1986;154(3):596–601.\nKobayashi H, et al. Revisiting estrogen-dependent signaling pathways in endometriosis: potential targets for non-hormonal therapeutics. Eur J Obstet Gynecol Reprod Biol. 2021;258:103–10.\nPu H, et al. Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system. J Steroid Biochem Mol Biol. 2023;227:106199.\nAngioni S, et al. New trends of progestins treatment of endometriosis. Gynecol Endocrinol. 2014;30(11):769–73.\nBrichant G, et al. New therapeutics in endometriosis: a review of hormonal, non-hormonal, and non-coding RNA treatments. Int J Mol Sci. 2021;22(19):10498.\nResta C, et al. Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023;15(4):e38136.\nYan H, et al. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis. Fertil Steril. 2022;118(6):1102–16.\nDe Corte P, et al. Endometriosis and risk of depression among oral contraceptive users: a pooled analysis of cohort studies from 13 countries. Hum Reprod. 2025;40(3):479–86.\nTan Y, et al. Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues. Nat Cell Biol. 2022;24(8):1306–18.\nChan RW, Ng EH, Yeung WS. Identification of cells with colony-forming activity, self-renewal capacity, and multipotency in ovarian endometriosis. Am J Pathol. 2011;178(6):2832–44.\nCousins FL, Dorien FO, Gargett CE. Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018;50:27–38.\nUlukus M, Cakmak H, Arici A. The role of endometrium in endometriosis. J Soc Gynecol Investig. 2006;13(7):467–76.\nBergqvist A, Fernö M. Endometriosis: oestrogen and progesterone receptors in endometriotic tissue and endometrium: comparison of different cycle phases and ages*. Hum Reprod. 1993;8(12):2211–7.\nJänne O, et al. Estrogen and progestin receptors in endometriosis lesions: comparison with endometrial tissue. Am J Obstet Gynecol. 1981;141(6):562–6.\nBulun SE, et al. Estrogen receptor-β, estrogen receptor-α, and progesterone resistance in endometriosis. Semin Reprod Med. 2010;28(01):036–43.\nChantalat E, et al. Estrogen receptors and endometriosis. Int J Mol Sci. 2020;21(8):2815.\nHarada T, et al. Apoptosis in human endometrium and endometriosis. Hum Reprod Update. 2004;10(1):29–38.\nKinkel K, et al. Diagnosis of endometriosis with imaging: a review. Eur Radiol. 2006;16(2):285–98.\nKido A, et al. MRI in the diagnosis of endometriosis and related diseases. Korean J Radiol. 2022;23(4):426–45.\nMonnaka VU, et al. Overview of miRNAs for the non-invasive diagnosis of endometriosis: evidence, challenges and strategies. A systematic review. Einstein (São Paulo). 2021;19:eRW5704.\nMoein Mahini S, et al. Non-invasive diagnosis of endometriosis: immunologic and genetic markers. Clin Chim Acta. 2023;538:70–86.\nScheck SM, et al. Non-invasive tests for endometriosis are here; how reliable are they, and what should we do with the results? Aust N Z J Obstet Gynaecol. 2024;64(2):168–70.\nKalaitzopoulos DR, et al. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health. 2021;21(1):397.\nKoninckx PR, et al. Pathogenesis based diagnosis and treatment of endometriosis. Front Endocrinol. 2021;12:745548.\nVissers G, et al. The role of fibrosis in endometriosis: a systematic review. Hum Reprod Update. 2024;30(6):706–50.\nViganò P, et al. Cellular components contributing to fibrosis in endometriosis: a literature review. J Minim Invasive Gynecol. 2020;27(2):287–95.\nCranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017;96(6):633–43.\nHeard ME, et al. High-fat diet promotion of endometriosis in an immunocompetent mouse model is associated with altered peripheral and ectopic lesion redox and inflammatory status. Endocrinology. 2016;157(7):2870–82.\nLi Y, et al. Progesterone alleviates endometriosis via inhibition of uterine cell proliferation, inflammation and angiogenesis in an immunocompetent mouse model. PLoS One. 2016;11(10):e0165347.\nWieser F, et al. Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis. Fertil Steril. 2012;97(6):1430–7.\nHe Y, et al. Re-evaluation of mouse models of endometriosis for pathological and immunological research. Front Immunol. 2022;13:986202.\nWang N, et al. A red fluorescent nude mouse model of human endometriosis: advantages of a non-invasive imaging method. Eur J Obstet Gynecol Reprod Biol. 2014;176:25–30.\nPerelló M, et al. Oral administration of pentoxifylline reduces endometriosis-like lesions in a nude mouse model. Reprod Sci. 2017;24(6):911–8.\nMa Y, He Y. Study of an antiangiogenesis gene therapy with endostatin on endometriosis in the nude mouse model. Clin Exp Obstet Gynecol. 2014;41(3):328–34.\nBruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metabol. 2009;94(7):2489–94.\nNisolle M, Casanas-Roux F, Donnez J. Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril. 2000;74(2):306–12.\nTaniguchi F, et al. Animal models for research on endometriosis. Front Biosci (Elite Ed). 2021;13(1):37–53.\nLaganà AS, et al. Translational animal models for endometriosis research: a long and windy road. Ann Transl Med. 2018;6(22):431.\nTejada MA, et al. Rodent animal models of endometriosis-associated pain: unmet needs and resources available for improving translational research in endometriosis. Int J Mol Sci. 2023;24(3):2422.\nBurns KA, et al. Endometriosis in the mouse: challenges and progress toward a ‘best fit’ murine model. Front Physiol. 2022;12:806574.\nNishimoto-Kakiuchi A, et al. Spontaneous endometriosis in cynomolgus monkeys as a clinically relevant experimental model. Hum Reprod. 2018;33(7):1228–36.\nHarirchian P, et al. Lesion kinetics in a non-human primate model of endometriosis. Hum Reprod. 2012;27(8):2341–51.\nBraundmeier AG, Fazleabas AT. The non-human primate model of endometriosis: research and implications for fecundity. Mol Hum Reprod. 2009;15(10):577–86.\nLe N, et al. Effects of endometriosis on immunity and mucosal microbial community dynamics in female olive baboons. Sci Rep. 2022;12(1):1590.\nBishop CV, et al. The combined impact of testosterone and Western-style diet on endometriosis severity and progression in rhesus macaques†. Biol Reprod. 2022;108(1):72–80.\nFogg K, et al. Roadmap on biomaterials for women’s health. J Phys Mater. 2023;6(1):012501.\nStejskalová A, et al. In vitro modelling of the physiological and diseased female reproductive system. Acta Biomater. 2021;132:288–312.\nRodrigues J, et al. 3D in vitro model (R)evolution: unveiling tumor-stroma interactions. Trends Cancer. 2021;7(3):249–64.\nIrfan Maqsood M, et al. Immortality of cell lines: challenges and advantages of establishment. Cell Biol Int. 2013;37(10):1038–45.\nKolliopoulos V, et al. Donor sex and passage conditions influence MSC osteogenic response in mineralized collagen scaffolds. Adv Healthc Mater. 2024;13(27):2400039.\nNikoo S, et al. Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics. Mol Hum Reprod. 2014;20(9):905–18.\nMiyazaki K, et al. Generation of progesterone-responsive endometrial stromal fibroblasts from human induced pluripotent stem cells: role of the WNT/CTNNB1 pathway. Stem Cell Rep. 2018;11(5):1136–55.\nGołąbek-Grenda A, Olejnik A. In vitro modeling of endometriosis and endometriotic microenvironment – challenges and recent advances. Cell Signal. 2022;97:110375.\nBlack V, et al. Modelling endometriosis using in vitro and in vivo systems. Int J Mol Sci. 2025;26(2):580.\nCheng Y-H, et al. A preliminary investigation of the roles of endometrial cells in endometriosis development via in vitro and in vivo analyses. Int J Mol Sci. 2024;25(7):3873.\nZeitvogel A, Baumann R, Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol. 2001;159(5):1839–52.\nBanu SK, et al. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril. 2008;90(4):972–87.\nBrueggmann D, et al. Novel three-dimensional in vitro models of ovarian endometriosis. J Ovarian Res. 2014;7(1):17.\nde Joliniere J, et al. Human endometriosis-derived permanent cell line (FbEM-1): establishment and characterization. Hum Reprod Update. 1997;3(2):117–23.\nSong Y, et al. Establishment of an immortalized endometriotic stromal cell line from human ovarian endometrioma. Reprod Sci. 2020;27(11):2082–91.\nSong Y, et al. Spheroids as a model for endometriotic lesions. JCI Insight. 2023;8(11):e160815.\nGuay S, Akoum A. Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology. Reproduction. 2007;134(3):525–34.\nZhao J, et al. Effect and mechanisms of kaempferol against endometriosis based on network pharmacology and in vitro experiments. BMC Complementary Med Ther. 2022;22(1):254.\nWendel JRH, et al. Three-dimensional biofabrication models of endometriosis and the endometriotic microenvironment. Biomedicines. 2020;8(11):525.\nStejskalová A, et al. Collagen I triggers directional migration, invasion and matrix remodeling of stroma cells in a 3D spheroid model of endometriosis. Sci Rep. 2021;11(1):4115.\nMatsuzaki S, et al. Effects of matrix stiffness on epithelial to mesenchymal transition-like processes of endometrial epithelial cells: implications for the pathogenesis of endometriosis. Sci Rep. 2017;7(1):44616.\nCanosa S, et al. Angiogenic properties of endometrial mesenchymal stromal cells in endothelial co-culture: an in vitro model of endometriosis. Mol Hum Reprod. 2017;23(3):187–98.\nKrálíčková M, et al. Altered immunity in endometriosis: what came first? Immunol Investig. 2018;47(6):569–82.\nLoh F-H, et al. Effects of peritoneal macrophages from women with endometriosis on endometrial cellular proliferation in an in vitro coculture model. Fertil Steril. 1999;72(3):533–8.\nScheerer C, et al. Characterization of endometriosis-associated immune cell infiltrates (EMaICI). Arch Gynecol Obstet. 2016;294(3):657–64.\nChen S, Chai X, Wu X. Bioinformatical analysis of the key differentially expressed genes and associations with immune cell infiltration in development of endometriosis. BMC Genomic Data. 2022;23(1):20.\nWang X, et al. The abundance and function of neutrophils in the endometriosis systemic and pelvic microenvironment. Mediat Inflamm. 2023;2023(1):1481489.\nIzumi G, et al. Involvement of immune cells in the pathogenesis of endometriosis. J Obstet Gynaecol Res. 2018;44(2):191–8.\nBerbic M, et al. Macrophage expression in endometrium of women with and without endometriosis. Hum Reprod. 2008;24(2):325–32.\nTakebayashi A, et al. Subpopulations of macrophages within eutopic endometrium of endometriosis patients. Am J Reprod Immunol. 2015;73(3):221–31.\nTakamura M, et al. Simultaneous detection and evaluation of four subsets of CD4+ T lymphocyte in lesions and peripheral blood in endometriosis. Am J Reprod Immunol. 2015;74(6):480–6.\nSeli E, Arici A. Endometriosis: interaction of immune and endocrine systems. Semin Reprod Med. 2003;21(02):135–44.\nAbramiuk M, et al. The role of the immune system in the development of endometriosis. Cells. 2022;11(13):2028.\nMilewski Ł, et al. Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-8. J Reprod Immunol. 2011;91(1):64–70.\nTabatabaei F, et al. Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis. BMC Womens Health. 2023;23(1):576.\nThiruchelvam U, Wingfield M, O’Farrelly C. Natural killer cells: key players in endometriosis. Am J Reprod Immunol. 2015;74(4):291–301.\nMatsuoka S, et al. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. Am J Reprod Immunol. 2005;53(5):249–54.\nHoogstad-van Evert J, et al. The promises of natural killer cell therapy in endometriosis. Int J Mol Sci. 2022;23(10):5539.\nYang H-L, et al. The crosstalk between endometrial stromal cells and macrophages impairs cytotoxicity of NK cells in endometriosis by secreting IL-10 and TGF-β. Reproduction. 2017;154(6):815–25.\nHogg C, Horne AW, Greaves E. Endometriosis-associated macrophages: origin, phenotype, and function. Front Endocrinol. 2020;11:7.\nMontagna P, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril. 2008;90(1):156–64.\nLi MQ, et al. CD4+Foxp3+ regulatory T cell differentiation mediated by endometrial stromal cell-derived TECK promotes the growth and invasion of endometriotic lesions. Cell Death Dis. 2014;5(10):e1436.\nPodgaec S, et al. CD4+CD25highFoxp3+ cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol. 2012;68(4):301–8.\nHudecek R, et al. Blocking of EphA2 on endometrial tumor cells reduces susceptibility to Vδ1 gamma-delta T-cell-mediated killing. Front Immunol. 2021;12:752646.\nPawłowska A, et al. γδ T lymphocytes as a double-edged sword—state of the art in gynecological diseases. Int J Mol Sci. 2022;23(23):14797.\nLaschke MW, Menger MD. Basic mechanisms of vascularization in endometriosis and their clinical implications. Hum Reprod Update. 2018;24(2):207–24.\nNisolle M, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis **Supported in part by Fonds de la Recherche Scientifique Médicale, grant 3.4587.90, Brussels, Belgium. Fertil Steril. 1993;59(3):681–4.\nKuroda K, et al. Vascular density of peritoneal endometriosis using narrow-band imaging system and vascular analysis software. J Minim Invasive Gynecol. 2009;16(5):618–21.\nBoretto M, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019;21(8):1041–51.\nGunther K, et al. Endometriosis is not the endometrium: reviewing the over-representation of eutopic endometrium in endometriosis research. Elife. 2025;14:e103825.\nKao A-P, et al. Comparative study of human eutopic and ectopic endometrial mesenchymal stem cells and the development of an in vivo endometriotic invasion model. Fertil Steril. 2011;95(4):1308–15.e1.\nTheriault HS, et al. Matrix tropism influences endometriotic cell attachment patterns. Adv Funct Mater. 2025;35:02777.\nDelbandi A-A, et al. Eutopic and ectopic stromal cells from patients with endometriosis exhibit differential invasive, adhesive, and proliferative behavior. Fertil Steril. 2013;100(3):761–9.\nZhao X. 1 – Introduction to bioactive materials in medicine. In: Zhao X, Courtney JM, Qian H, editors. Bioactive materials in medicine. Woodhead Publishing; 2011. p. 1–13.\nSoni UK, et al. A high level of TGF-B1 promotes endometriosis development via cell migration, adhesiveness, colonization, and invasiveness†. Biol Reprod. 2018;100(4):917–38.\nLiu H, et al. GLI1 is increased in ovarian endometriosis and regulates migration, invasion and proliferation of human endometrial stromal cells in endometriosis. Ann Transl Med. 2019;7(22):663.\nLeiva MC, et al. Increased chemotactic activity of peritoneal fluid in patients with endometriosis. Am J Obstet Gynecol. 1993;168(2):592–8.\nWitz CA, et al. An in vitro model to study the pathogenesis of the early endometriosis lesion. Ann N Y Acad Sci. 2002;955(1):296–307.\nFu X, et al. Osteopontin regulates endometrial stromal cell migration in endometriosis through the PI3K pathway. Reprod Sci. 2021;28(2):435–46.\nIwabe T, et al. Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metabol. 2000;85(2):824–9.\nWang N. Review of cellular mechanotransduction. J Phys D Appl Phys. 2017;50(23):233002.\nNaqvi SM, McNamara LM. Stem cell mechanobiology and the role of biomaterials in governing mechanotransduction and matrix production for tissue regeneration. Front Bioeng Biotechnol. 2020;8:597661.\nKobayashi H. Invasive capacity of heterotopic endometrium. Gynecol Obstet Investig. 2000;50(Suppl. 1):26–32.\nQiu X-M, et al. IL-2 and IL-27 synergistically promote growth and invasion of endometriotic stromal cells by maintaining the balance of IFN-γ and IL-10 in endometriosis. Reproduction. 2020;159(3):251–60.\nGaetje R, et al. Invasiveness of endometriotic cells in vitro. Lancet. 1995;346(8988):1463–4.\nFasciani A, et al. Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis. Fertil Steril. 2003;80(5):1137–43.\nEsfandiari N, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril. 2007;87(2):257–62.\nFrancés-Herrero E, et al. Improved models of human endometrial organoids based on hydrogels from decellularized endometrium. J Pers Med. 2021;11(6):504.\nMacchione MA, et al. Chapter 2 – Synthetic and semi-synthetic polymers for pharmaceutical applications. In: Nayak AK, et al., editors. Advances and challenges in pharmaceutical technology. Academic Press; 2021. p. 45–73.\nGnecco JS, et al. Organoid co-culture model of the human endometrium in a fully synthetic extracellular matrix enables the study of epithelial-stromal crosstalk. Med. 2023;4(8):554–579.e9.\nZambuto SG, Clancy KBH, Harley BAC. A gelatin hydrogel to study endometrial angiogenesis and trophoblast invasion. Interface Focus. 2019;9(5):20190016.\nKim J, et al. Synthetic hydrogel supports the function and regeneration of artificial ovarian tissue in mice. NPJ Regen Med. 2016;1:16010.\nWynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.\nShomali N, et al. Exosomes: emerging biomarkers and targets in folliculogenesis and endometriosis. J Reprod Immunol. 2020;142:103181.\nFreger S, Leonardi M, Foster W. Exosomes and their cargo are important regulators of cell function in endometriosis. Reprod Biomed Online. 2021;43(3):370–8.\nSharkey AM, et al. Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab. 2000;85(1):402–9.\nLebovic DI, et al. Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1β. Mol Hum Reprod. 2000;6(3):269–75.\nAkoum A, et al. Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro. Mol Hum Reprod. 2001;7(9):859–66.\nChung MS, Han SJ. Endometriosis-associated angiogenesis and anti-angiogenic therapy for endometriosis. Front Glob Womens Health. 2022;3:856316.\nZheng W, et al. Anti-angiogenic alternative and complementary medicines for the treatment of endometriosis: a review of potential molecular mechanisms. Evid Based Complement Alternat Med. 2018;2018(1):4128984.\nZambuto SG, et al. Role of extracellular matrix biomolecules on endometrial epithelial cell attachment and cytokeratin 18 expression on gelatin hydrogels. ACS Biomater Sci Eng. 2022;8(9):3819–30.\nZambuto SG, et al. Response of neuroglia to hypoxia-induced oxidative stress using enzymatically crosslinked hydrogels. MRS Commun. 2020;10(1):83–90.\nZambuto SG, et al. Cell chirality of micropatterned endometrial microvascular endothelial cells. Adv Healthc Mater. 2024;13(12):e2303928.\nZambuto SG, et al. Endometrial decidualization status modulates endometrial microvascular complexity and trophoblast outgrowth in gelatin methacryloyl hydrogels. NPJ Womens Health. 2024;2(1):22.\nChen Q, et al. Emerging strategies for the treatment of endometriosis. Biomed Technol. 2024;7:46–62.\nYuxue J, et al. Applications of nanomaterials in endometriosis treatment. Front Bioeng Biotechnol. 2023;11:1184155.\nPeng Y, et al. Emerging bioengineering breakthroughs in precision diagnosis and therapy for endometriosis and adenomyosis. J Mater Chem B. 2025;13(3):742–62.\nZhao M-D, et al. Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation. Int J Nanomedicine. 2016;11:1323–36.\nLiu Q, et al. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci. 2017;96:542–50.\nWang Y-C, et al. Polyglycolic acid/chitosan glue and apoptosis of endometriotic cells. Fertil Steril. 2005;84(1):75–81.\nde Almeida Borges VR, et al. Development and pharmacological evaluation of in vitro nanocarriers composed of lamellar silicates containing copaiba oil-resin for treatment of endometriosis. Mater Sci Eng C. 2016;64:310–7.\nSingh AK, Chakravarty B, Chaudhury K. Nanoparticle-assisted combinatorial therapy for effective treatment of endometriosis. J Biomed Nanotechnol. 2015;11(5):789–804.\nZhang H, et al. Hyaluronic acid-modified magnetic iron oxide nanoparticles for MR imaging of surgically induced endometriosis model in rats. PLoS One. 2014;9(4):e94718.\nAcknowledgments\nThe authors would like to acknowledge funding sources, specifically the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Numbers R01 HD118600 (BACH) and T32 HD108075 (HST). This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We acknowledge the use of BioRender to create figures.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2026 The Author(s), under exclusive license to Springer Nature Switzerland AG\nAbout this chapter\nCite this chapter\nTheriault, H.S., Harley, B.A.C. (2026). Biomaterial Tools for Modeling Endometriosis. In: Zambuto, S.G., Oyen, M.L. (eds) Biomaterials for Women’s Health Engineering. Springer, Cham. https://doi.org/10.1007/978-3-032-10745-9_9\nDownload citation\nDOI: https://doi.org/10.1007/978-3-032-10745-9_9\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-032-10744-2\nOnline ISBN: 978-3-032-10745-9\neBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)","source_license":"CC0","license_restricted":false}